Macquarie Group
TRIL

Macquarie Group’s Trillium Therapeutics Inc. TRIL Stock Holding History

Macquarie Group’s Portfolio TRIL Stock Details TRIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-163,326
Closed -$2.4M – 2501
2020
Q4 		$2.4M Buy
+163,326
New +$2.36M ﹤0.01% 1054

Other funds holding TRIL

EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

Macquarie Group's TRIL Position: Q1 2021 in Review

Macquarie Group sold out of Trillium Therapeutics Inc. (TRIL) in Q1 2021, closing a stake of 163,326 shares — an estimated $2.4M sold.

Macquarie Group first reported a position in TRIL in Q4 2020 and held it in 1 quarter. The position peaked at $2.4M in Q4 2020. 125 funds tracked by Wall St. Rank hold TRIL as of Q1 2021.

  • Macquarie Group reported no remaining Trillium Therapeutics Inc. position as of Q1 2021 after selling out during the quarter.
  • Macquarie Group sold 163,326 Trillium Therapeutics Inc. shares in Q1 2021, an estimated $2.4M.
  • Macquarie Group first reported a position in Trillium Therapeutics Inc. in Q4 2020 and held it in 1 quarter.
  • Macquarie Group's Trillium Therapeutics Inc. position peaked at $2.4M in Q4 2020.
  • 125 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q1 2021.

Based on Macquarie Group's 13F filing for Q1 2021, filed 14 May 2021.